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Abstract
Background: More than a million diagnostic cardiac catheterizations are performed annually in the US for
evaluation of coronary artery anatomy and the presence of atherosclerosis. Nearly half of these patients have no
significant coronary lesions or do not require mechanical or surgical revascularization. Consequently, the ability to
rule out clinically significant coronary artery disease (CAD) using low cost, low risk tests of serum biomarkers in
even a small percentage of patients with normal coronary arteries could be highly beneficial.
Methods: Serum from 359 symptomatic subjects referred for catheterization was interrogated for proteins involved
in atherogenesis, atherosclerosis, and plaque vulnerability. Coronary angiography classified 150 patients without
flow-limiting CAD who did not require percutaneous intervention (PCI) while 209 required coronary
revascularization (stents, angioplasty, or coronary artery bypass graft surgery). Continuous variables were compared
across the two patient groups for each analyte including calculation of false discovery rate (FDR ≤ 1%) and Q value
(P value for statistical significance adjusted to ≤ 0.01).
Results: Significant differences were detected in circulating proteins from patients requiring revascularization including
increased apolipoprotein B100 (APO-B100), C-reactive protein (CRP), fibrinogen, vascular cell adhesion molecule 1
(VCAM-1), myeloperoxidase (MPO), resistin, osteopontin, interleukin (IL)-1b, IL-6, IL-10 and N-terminal fragment protein
precursor brain natriuretic peptide (NT-pBNP) and decreased apolipoprotein A1 (APO-A1). Biomarker classification
signatures comprising up to 5 analytes were identified using a tunable scoring function trained against 239 samples
and validated with 120 additional samples. A total of 14 overlapping signatures classified patients without significant
coronary disease (38% to 59% specificity) while maintaining 95% sensitivity for patients requiring revascularization.
Osteopontin (14 times) and resistin (10 times) were most frequently represented among these diagnostic signatures.
The most efficacious protein signature in validation studies comprised osteopontin (OPN), resistin, matrix
metalloproteinase 7 (MMP7) and interferon g (IFNg) as a four-marker panel while the addition of either CRP or
adiponectin (ACRP-30) yielded comparable results in five protein signatures.
Conclusions: Proteins in the serum of CAD patients predominantly reflected (1) a positive acute phase,
inflammatory response and (2) alterations in lipid metabolism, transport, peroxidation and accumulation. There
were surprisingly few indicators of growth factor activation or extracellular matrix remodeling in the serum of CAD
patients except for elevated OPN. These data suggest that many symptomatic patients without significant CAD
could be identified by a targeted multiplex serum protein test without cardiac catheterization thereby eliminating
exposure to ionizing radiation and decreasing the economic burden of angiographic testing for these patients.
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Background
Coronary heart disease is the most prevalent chronic dis-
ease and the leading cause of death in the US, with more
than half a million newly diagnosed coronary artery dis-
ease (CAD) patients annually [1,2]. Cardiac catheterization
and coronary angiography are often necessary for defini-
tive evaluation of coronary artery anatomy, the presence
of coronary atherosclerosis and to determine the need for
interventional therapy. Despite the high prevalence of
CAD, approximately half of patients undergoing invasive
cardiac catheterization either have no significant coronary
lesions or do not require any mechanical or surgical form
of revascularization [3-5]. Thus, the procedure could be
eliminated in many cases if alternative, non-invasive tools
were available to assess the presence or absence of signifi-
cant CAD and confirm the need for angiography.
Clinical assessment of CAD represents a significant
medical and economic challenge comprising more than a
million coronary angiograms annually in the US alone
with demographics of aging and obesity forecasting grow-
ing demand [2-5]. The risk and expense of cardiac cathe-
terization (ionizing radiation, contrast media, morbidity)
and the large number of patients with normal coronary
arteries or ‘non-significant’ CAD undergoing invasive
angiography warrant development of alternative tests for
CAD without cardiac catheterization [5]. While progress
has been made using non-invasive computed tomography
(CT) particularly for its negative predictive value, CT
incorporates significant exposure to ionizing radiation
with considerably lower resolution than catheterization-
based angiography [6].
Efforts to identify circulating biomarkers for CAD have
shown promise by interrogating transcriptional profiles
of patient blood cells and plasma for unique mRNA and
microRNA signatures [7,8]. Since extracellular RNA
undergoes rapid degradation, prospective mRNA signa-
tures were derived predominantly from nucleated blood
cells while the miRNAs identified in plasma were likely
protected in circulating vesicles or bound to protective
protein complexes [9]. Consequently, the utility of RNA
as an indicator of CAD is constrained by its selective cell
source in the bloodstream, the friability of the ribonu-
cleotide targets and the arduous process of RNA capture,
purification, amplification and analysis. In contrast, circu-
lating proteins are more stable than RNA in blood and
serum with several individual markers identified pre-
viously as prospective biomarkers for the presence of
atherosclerosis, myocardial infarction, heart failure, or
markers of pathways involved in these cardiac conditions
such as inflammation, thrombosis, plaque stability, and
oxidative stress, for example, troponin C, pro-brain
natriuretic peptide (BNP) and C-reactive protein (CRP)
[10,11]. However, circulating biomarkers have proven to
be of limited value in clinical tests to diagnose coronary
artery disease antecedent to a cardiac event, primarily
because most studies have focused on single or at most a
few markers to make the diagnosis [12]. The difficulty in
identifying predictive factors of CAD in blood or serum
is compounded by the multifactorial etiology of coronary
artery disease which makes early diagnosis by a single,
endpoint marker unlikely prior to activation of a com-
mon ischemic pathway or until significant myocardial
compromise has occurred.
The hypothesis underlying the current study was that
coronary artery disease status can be assessed via indivi-
dual and/or combinatorial protein changes in serum that
assess multiple pathways of atherosclerosis as a low-risk,
non-invasive approach for screening of symptomatic
patients, that is, patients referred for cardiac catheteriza-
tion. The study targeted patients who were referred for a
clinically-indicated cardiac catheterization from either
the emergency room or outpatient cardiac clinic in a
major metropolitan center who presented with symptoms
of heart disease. All patients had blood drawn prior to
coronary angiography and revascularization. By analyzing
a compendium of 41 circulating protein targets asso-
ciated with atherogenesis, inflammation, thrombosis, and
plaque vulnerability, we discovered 12 diverse proteins
expressed across a broad dynamic range that were signifi-
cantly different concomitant with the need for these
patients to undergo therapeutic intervention including
stent placement, angioplasty, or coronary artery bypass
graft surgery (CABG). We also tested multiplex biomar-
ker signatures for the potential to discriminate patients
lacking significant coronary artery disease from patients
with CAD requiring corrective interventional therapy. In
particular, the ability to rapidly and decisively rule out
clinically significant coronary artery disease using a
potentially low cost, low risk blood test in even a small
percentage of patients with normal coronary arteries
could be highly beneficial.
Methods
Patient group
Samples comprised serum from among 359 subjects
referred for a clinically-indicated cardiac catheterization
for symptoms of CAD. The study was performed accord-
ing to the Department of Health and Human Services
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Code of Federal Regulations (45 CFR 46) for the protec-
tion of human research subjects including ethical consid-
erations consistent with the Office for Human Research
Protections. Blood was collected following a genetic
banking protocol (#990835) approved by the University
of Pittsburgh Institutional Review Board (IRB). Only
patients who signed the approved IRB voluntary
informed consent document for this study were included
(11 January 2000 to 21 July 2004). Venous blood (5 ml)
was drawn into a red top vacutainer serum tube (Becton
Dickinson #366430, Franklin Lakes, NJ, USA) and placed
upright 30 to 60 minutes until clot formation. The tubes
were centrifuged in a swinging bucket rotor (1,300 g × 20
min) and the serum was pipetted into 1.5 ml cryovials for
storage at -80°C. All 359 patients underwent diagnostic
coronary angiography and 209 required interventional
therapy comprising stent placement, angioplasty or
CABG. The other patients had normal or clinically insig-
nificant coronary artery disease, that is, angiography
revealed absence of any vessel obstruction or non-critical,
< 50% obstruction in any epicardial vessel. Thus, serum
samples comprised one patient group based on clinical
symptoms but two outcome groups based on therapeutic
intervention.
Proteomics analysis
Samples underwent a first thaw on ice to apportion into
200 μl aliquots for -80°C storage until analysis. An
exploratory study of 56 samples was performed using
fluorokine multianalyte profiling (xMAP) of 33 proteins
(Luminex 100; Luminex, Austin, TX, USA) to determine
serum dilution factors and rule out targets lacking sta-
tistical discrimination. The assay used polystyrene
microspheres incorporating differing ratios of two fluor-
ophores yielding different spectrally addressed bead sets
each conjugated with a biotinylated protein-specific cap-
ture antibody. Assays were processed in duplicate in a
randomized, blinded manner regarding patient out-
comes, including generation of a standard curve using
recombinant target proteins. Each 96 well microplate
was incubated overnight at 4°C on a microtiter shaker.
Wells were washed with buffer (3 ×) and a secondary
antibody added to each well for incubation (2 h, room
temperature) followed by streptavidin-phycoerythrin (0.5
h, room temperature, agitation). The wells were then
washed (2 ×), assay buffer was added, and samples were
analyzed using the Bio-Plex suspension array system and
Bio-Plex Manager software 4.0 (Bio-Rad Laboratories,
Hercules, CA, USA). Absolute quantities were deter-
mined by comparison to the five-point standard curve
for each analyte.
The Searchlight Protein Array System (Aushon Biosys-
tems, Inc, Billerica, MA, USA) was used to interrogate
patient serum samples at 2 different stages (stage 1: 239
samples, 24 analytes; stage 2: 120 samples, 10 analytes).
First, 239 samples were evaluated for 24 analytes over con-
centration ranges defined by the preliminary study of 56
samples. The assay comprised a multiplex sandwich
ELISA of monoclonal capture antibodies spotted in planar
arrays in 96-well microtiter plates. After serum incubation
and washing, a second biotinylated monoclonal antibody
to a different site from the capture epitope was introduced
and streptavidin-horseradish peroxidase (HRP) subse-
quently bound to the biotin site. Luminol enhancer/perox-
idase solution was added and the HRP catalyzed oxidation
of luminol to 3-aminophthalate resulting in light emission
at 428 nm. A chemiluminescent image was acquired and
processed using a four-parameter curve fit program
(SearchLight Array Analyst Software) to compare the
experimental samples to the recombinant calibration
curve run in parallel wells to derive absolute concentra-
tions adjusted for dilution and quality values.
The largest SearchLight panel simultaneously evaluated
seven analytes diluted 1:1 (volume/volume) (dilution factor
(df) = 2 ×) in assay buffer (RPMI1640 without phenol red
+ 10% heat inactivated FBS) including interferon g (IFNg),
interleukin 1b (IL-1b), IL-6, IL-10, matrix metalloprotei-
nase protein 1 (MMP1), thrombomodulin (TM) and
tumor necrosis factor a (TNFa). Leptin, platelet endothe-
lial cell adhesion molecule 1 (PECAM-1), endothelial leu-
kocyte adhesion molecule 1 (E-selectin), monocyte
chemoattractant protein 1 (MCP-1), MMP7 and vascular
cell adhesion molecule 1 (VCAM-1) were assayed together
at 25 × dilution factor. Tissue inhibitor of metalloprotei-
nase 1 (TIMP-1), fibrinogen, resistin, leukocyte selectin
(L-selectin) and myeloperoxidase (MPO) (df = 1,000 ×)
were analyzed in a five-analyte panel. Adiponectin (ACRP-
30) and C-reactive protein (CRP) were assayed together at
a dilution factor of 5,000 ×. Apolipoprotein A1 (APO-A1,
df = 50,000 ×), apolipoprotein B100 (APO-B100, df =
10,000 ×), osteopontin (OPN, df = 10 ×) and N-terminal
fragment protein precursor brain natriuretic peptide (NT-
pBNP, df = 2 ×) were interrogated independently.
A second stage study of 120 additional serum samples
was repeated twice to validate the previous findings
from the 239 sample set and to test assay reproducibility
across different reagent and planar array lots. The sam-
ple prep, quality control (QC), methodological protocols
for recombinant protein calibration profiles, serial dilu-
tions and serum assays were performed as before but
using fewer panels and smaller analyte configurations.
These included MPO, fibrinogen and resistin (df = 1,000
×) in a three-multiplex configuration, ACRP-30 and
APO-B100 together (df = 10,000 ×), MMP7 and
VCAM-1 together (df = 25 ×) and osteopontin (df = 10
×), IFN-g (df = 2 ×) and IL-1b (df = 2 ×) separately.
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Statistical analysis
Patients were operationally defined as ‘symptomatic’ by
referral for a clinically indicated catheterization. Based on
coronary angiography outcome, the serum samples were
classified from patients with ‘normal’ coronary arteries,
that is, no clinically significant coronary artery disease (n =
150) or patients with coronary disease requiring therapy
including stent placement, angioplasty or CABG (n =
209). The hypothesis undergoing statistical testing was
that serum proteins were significantly different between
the two patient outcome classifications. Statistical analysis
was initially performed on 239 samples in stage 1 evalu-
ated for 24 analytes comprising 101 serum samples from
patients with clinically normal coronary arteries and 138
samples from patients requiring percutaneous intervention
(PCI). These samples were also used to develop and train
a scoring function algorithm. A second stage validation
study (n = 120) interrogating 10 analytes was subsequently
performed to validate the algorithm. Results from all of
these studies were combined for statistical comparison.
Continuous variables were compared (Partek Genomics
Suite, St. Louis, MO, USA) using the unpaired Student’s
t test across the two patient groups for each analyte
including calculation of a false discovery rate (FDR) and
Q value as the minimum positive FDR for rejecting a sta-
tistic [13]. Significant differential expression of proteins
was defined at an FDR of ≤ 1% with Q = 0.01 and statisti-
cal significance for P values was adjusted to ≤ 0.01. Cate-
gorical variables were compared using the Pearson’s
c2 test.
Algorithm development and validation of selected
markers
Data for all 24 markers interrogated in stage 1 were evalu-
ated as randomized, multimarker signatures to classify
patients with CAD requiring treatment versus patients
without clinically significant CAD. A scoring function (SF)
algorithm was generated for all protein combinations as
disease ‘signatures’ including 24 ‘artificial’ markers derived
by randomly scrambling the data (see Additional File 1).
The SF for each signature was a linear combination of nat-
ural logarithms of marker concentrations generated by
iterative computation. Monte Carlo optimization deter-
mined coefficients that provided highest diagnostic accu-
racy, that is, specificity (SP: identification of negatives for
significant CAD) for detecting patients with normal coron-
ary arteries while maintaining 95% sensitivity (SN: identifi-
cation of CAD requiring interventional therapy) for
patients with coronary artery disease. We ranked > 2
million combinations of 2 to 5 marker signatures compris-
ing the 24 actual and 24 ‘artificial’ markers for ability to
classify patients since combinations of 6 or more proteins
with high classification strength commonly contained an
artificial marker (see Additional file 2 Table S1). For each
signature of 2 to 5 markers, the top 50 panels with highest
SP for normal (while correctly detecting at least 95% of
the CAD patients) underwent cross validation testing
where 80% of participants were randomly selected as a
training set to build the optimal SF and the remaining
20% of participants were thenclassified using this SF. The
crossvalidation procedure was repeated 500 times and
average SP and SN were used to identify best performing
signatures.
Independent verification of the scoring function algo-
rithm was performed in 2 repeated studies of 120 serum
specimens from an additional cohort of symptomatic
patients with clinical characteristics matching the pre-
vious 239 patients. Concentration values for these sam-
ples were entered into the algorithm in a macro
subroutine program using the offset, coefficients and cut-
offs to detect CAD based on patient outcome. The results
of the 120-sample validation study were compared to the
diagnostic classification of each patient after coronary
catheterization and follow-up therapy to determine the
sensitivity and specificity of prospective signatures.
Results
Diagnostic coronary angiography revealed that 209 of the
patients in this study exhibited significant coronary artery
disease requiring therapeutic intervention while 150
patients did not exhibit clinically significant coronary
artery disease despite symptoms or other findings that
led to referral for cardiac catheterization. These two dis-
tinct outcome groups were otherwise identical upon
admission regarding clinical symptoms and physical
characteristics including gender, diabetic status, smoking
history, body surface area, basal metabolic rates, choles-
terol, LDL and creatinine values (see Table 1). Among
continuous variables, there were small albeit significant
differences in age, HDL levels and ejection fraction
between groups; but the differences were of minimal
diagnostic value and all patients required coronary angio-
graphy. Regarding categorical variables, there were no
significant differences in gender or diabetes between the
two groups; however, the number of patients with hyper-
tension was significantly higher in the CAD group.
All serum samples were collected, processed, stored and
analyzed in an identical manner to limit the effect of prea-
nalytic variability including differential protein degradation
among specimens. Significant differences were detected in
12 serum proteins (Q value = 0.01; P < 0.01) between
patients diagnosed as having CAD requiring intervention
and those with non-significant CAD after diagnostic cor-
onary angiography. The differences detected in the stage 1
study (n = 239) were reinforced by the additional samples
from the validation study (n = 120) (see Table 2). APO-A1
and APO-B100 were among the highest expressed pro-
teins overall averaging approximately 300 μg/ml of serum
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(Figure 1). APO-A1 fell significantly in patients with sig-
nificant CAD versus non-significant CAD while APO-
B100 was significantly increased. Within the same concen-
tration range, fibrinogen was present at levels typically
exceeding 1 μg/ml with values fivefold higher in patients
with significant CAD (Figure 1). At serum concentrations
from 10 ng to 1 μg/ml serum, five proteins were signifi-
cantly higher in CAD patients. Specifically, CRP, VCAM-
1, MPO, resistin and osteopontin were 1.2 to 3.1-fold
higher than patients with non-significant CAD (Figure 2).
Four analytes, IL-6, IL-1b, IL-10 and NT-pBNP were sig-
nificantly higher in the CAD group among analytes
detected in a range from 1 pg/ml to 1 ng/ml (Figure 3).
There were no significant statistical correlations between
any of these 12 analytes and age, ejection fraction or
hypertension status which were significantly but incre-
mentally different between the patient outcome groups.
No other analytes among the 41 interrogated targets were
significantly altered between the 2 groups of patient sam-
ples using either bead-based or planar platforms.
We identified 14 multiplex signatures of 2 to 5 proteins
each with the highest acuity to detect patients without sig-
nificant CAD (22.6% to 58.4% SP) while detecting 95% of
the significant CAD group (95% SN) in the stage 1 study
(see Additional file 2 Table S1). A total of 11 distinct pro-
teins were shared among the 14 signatures with osteopon-
tin (14 of 14), and resistin (10 of 14) most frequently
represented. There was a trend for protein signatures with
increased numbers of analytes to detect more normal
patients at a fixed sensitivity for CAD patients (95%) (two
proteins = 39.3% ± 0.3% vs five proteins = 50.0% ± 0.01%
of normal patients). However, a performance plateau was
reached at five biomarkers based on crossvalidated classi-
fier performance and the frequency of appearance of ‘arti-
ficial’ markers in test signatures exceeding five proteins.
Receiver operating characteristics analysis indicated that
these signatures were effective in discerning patients with-
out significant CAD. The area under the curve (AUC) for
the top signatures ranged from a low of 0.839 ± 0.028
(mean ± SD) for a two-protein signature (OPN, resistin)
to a maximum AUC of 0.845 using three biomarkers
(OPN, resistin, APO-B100) (Figure 4). These ROC curves
were compared to those generated by the Bayesian com-
pound covariate predictor algorithm for the same data set.
The area under the curve using the scoring function algo-
rithm exceeded that obtained by the Bayesian predictor in
every case. A clinical validation test of 120 additional
serum samples (49 normal, 71 patients requiring interven-
tion) was performed to test the performance of the scoring
function algorithm. In two separate studies, the best per-
forming multiplex signatures contained five proteins
(OPN, resistin, MMP7, IFNg with either CRP or ACRP-
30) and were able to correctly classify 88% and 92% of
patients requiring percutaneous intervention while deli-
neating 33% and 36% of the patients with normal coronary
arteriograms.
Discussion
Proteins were selected for evaluation in this study based
on their roles in mechanisms underlying atherogenesis,
Table 1 Clinical characteristics of the patient groups
Characteristic Average NOR SD N Average CAD SD N P value
HDL 50.5 18.2 85 41.6 9.9 141 < 0.001
Age 57.9 10.5 149 62.8 10.6 203 < 0.001
EF% 57.8 8.4 133 53.1 10.9 165 < 0.001
BMI 30.6 7.6 149 29.8 5.1 204 NS
BSA 2.1 0.3 149 2.0 0.2 204 NS
CHOL 196.7 36.2 87 192.2 45.9 140 NS
CREAT 1.0 0.7 100 1.0 1.0 123 NS
HT 171.4 9.5 148 171.6 10.1 204 NS
LDL 120.9 37.8 82 120.5 40.5 132 NS
WT 90.6 21.9 148 87.5 15.6 204 NS
NOR CAD
HYPTX 76 Y 74 N 150 125 Y 79 N 204 < 0.01
Gender 81 M 69 F 150 126 M 78 F 204 NS
DIAB 16 Y 134 N 150 31 Y 173 N 204 NS
Average and SD (standard deviations) for NOR patients (normal patients without clinically significant coronary artery disease) and CAD patients (patients with
coronary artery disease requiring therapeutic percutaneous intervention) are shown. N = number of samples for which parameters were available. P = statistical
P values for individual continuous parameters between the NOR and CAD groups with adjusted false discovery rate (FDR) cut-off for significance ≤ 0.01. P values
for categorical values were determined by Pearson’s c2 test. NS indicates that no significant statistical differences were detected. M/F indicates the number of
males and females in each group with age expressed in years, WT (weight) in kg and HT (height) in cm.
DIAB (diabetes) and HYPTX (hypertension) reported as the number of positive (Y) or negative (N) patients per group.
BSA = body surface area calculated in m2; BMI = body mass index (weight in kg/height in m2); CREAT = creatinine, mg/dl; CHOL = cholesterol, mg/dl; EF% =
ejection fraction, percentage; HDL = high-density lipoprotein, mg/dl; LDL = low-density lipoprotein, mg/dl.
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atherosclerosis and plaque instability including vascular
inflammation, thrombosis, aberrant lipid regulation, meta-
bolism hormones, and vascular smooth muscle and extra-
cellular matrix (ECM) remodeling [14]. The 41 preliminary
targets we interrogated were restricted by availability of
monoclonal antibody pairs optimized for use in the com-
mercial assay platforms. IL-1b, IL-6, IL-10 and VCAM-1,
were significantly elevated in patients with CAD in the pre-
sent study consistent with an injury-induced, inflammatory
response [15,16]. Elevated IL-1b and IL-6 have been asso-
ciated previously with acute phase protein induction and
may explain the concomitant significant increases in fibri-
nogen and CRP concentration we detected. CRP has long
been proposed as a surrogate marker for inflammatory
mediators in predicting coronary events while NT-pBNP
has been used as an indicator of left ventricular dysfunction
in CAD patient cohorts comparable to this study
[11,17,18]. Both analytes were significantly elevated in the
present study among patients requiring therapeutic inter-
vention and CRP was among the best single molecule
classifiers delineating 19% of normal samples while detect-
ing 95% of the patients with significant CAD.
Significant reciprocal changes were detected in APO-A1
and APO-B100 in CAD patients consistent with reports
defining aberrant lipid transport and accumulation as con-
tributory to atherosclerosis [19]. Mutations in the APO-
B100 gene cause autosomal dominant, hereditary familial
hypercholesterolemia and premature coronary artery dis-
ease due to defective ligand binding [19,20]. At the same
time, elevated APO-A1 is associated with a cardioprotec-
tive effect and enhancement of APO-A1 expression has
been proposed as a therapeutic strategy to inhibit ather-
oma formation [19,21]. The increased APO-B100 and
decreased APO-A1 levels in our patients requiring PCI
versus normal controls support these previous findings.
Myeloperoxidase was also significantly increased in CAD
patients associated with its role as a catalyst for lipid per-
oxidation at inflammation sites and as a marker of plaque
instability [22,23]. Resistin levels were elevated in the PCI
patients indicative of 1) metabolic shifts in lipid utilization
Table 2 Multiplex proteomics analysis of the coronary artery disease (CAD) and normal (NOR) patient groups
Average NOR SD N Average CAD SD N P value
OPN 16.4 ng 15.3 ng 149 40.6 ng 38.1 ng 206 < 0.001
VCAM 980.7 ng 493.8 ng 149 1,266.5 ng 492.5 ng 206 < 0.001
APO-A1 293.7 μg 257.4 μg 91 152.5 μg 134.5 μg 135 < 0.001
IL-6 0.6 ng 1.1 ng 101 1.5 ng 1.8 pg 135 < 0.001
MPO 538.2 ng 333.9 ng 147 731.1 ng 532.5 ng 206 < 0.001
IL-1b 56.9 pg 124.0 pg 149 109.0 pg 164.0 pg 206 < 0.005
NT-pBNP 33.3 pg 59.4 pg 91 103.2 pg 204.5 pg 135 < 0.005
Fibrinogen 4.8 μg 5.8 μg 149 25.6 μg 81.6 μg 206 < 0.005
APO-B100 273.2 μg 80.6 μg 149 300.6 μg 93.0 μg 206 < 0.005
Resistin 89.5 ng 63.0 ng 149 110.7 ng 77.0 ng 206 < 0.005
CRP 1.1 μg 2.4 μg 149 3.3 μg 9.7 μg 201 < 0.005
IL-10 3.3 pg 3.7 pg 91 7.6 pg 18.4 pg 135 < 0.005
MMP1 4.7 ng 2.3 ng 91 5.3 ng 2.4 ng 135 0.015 (NS)
Leptin 13.6 ng 18.0 ng 100 10.0 ng 16.0 ng 133 0.027 (NS)
ACRP30 5.9 μg 3.9 μg 149 5.2 μg 4.0 μg 206 0.027 (NS)
MMP7 4.8 ng 3.3 ng 149 5.2 ng 2.4 ng 206 0.045 (NS)
TNFa 22.7 pg 77.1 pg 91 14.7 pg 19.3 pg 135 0.059 (NS)
IFNg 3.6 pg 10.8 pg 149 4.7 pg 10.0 pg 206 0.069 (NS)
L-selectin 1.1 μg 0.2 μg 91 1.1 μg 0.3 μg 135 0.074 (NS)
MCP1 3.1 ng 3.7 ng 91 3.4 ng 3.4 ng 135 0.114 (NS)
PECAM-1 44.0 ng 32.1 ng 57 45.8 ng 27.2 ng 79 0.116 (NS)
TIMP1 321.3 ng 101.1 ng 91 327.2 ng 86.1 ng 135 0.116 (NS)
E-selectin 33.2 ng 19.2 ng 91 34.1 ng 16.6 ng 135 0.123 (NS)
TM 1.4 ng 0.8 ng 91 1.4 ng 0.4 ng 135 0.128 (NS)
Protein concentrations are reported in pg, ng or μg per ml of serum with adjusted P values for false discovery rate (FDR) at a cut-off for statistical significance
between the NOR and CAD groups = 0.01. NS indicates that no significant statistical differences were detected with the calculated P values provided in
parenthesis.
ACRP-30 = adiponectin; APO-A1 = apolipoprotein A1; APO-B100 = apolipoprotein B100; CRP = C-reactive protein; E-selectin = endothelial leukocyte adhesion
molecule 1; IFNg = interferon g; IL = interleukin; L-selectin = leukocyte selectin; MCP-1 = monocyte chemoattractant protein 1; MMP matrix metalloproteinase;
MPO = myeloperoxidase; NT-pBNP = N-terminal fragment protein precursor brain natriuretic peptide; OPN = osteopontin; PECAM-1 = platelet endothelial cell
adhesion molecule 1; TIMP-1 = tissue inhibitor of metalloproteinase 1; TM = thrombomodulin; TNFa = tumor necrosis factor a; VCAM-1 = vascular cell adhesion
molecule 1.
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and adipogenesis and/or 2) an inflammatory response with
resistin secreted from macrophages concomitant with the
release of proinflammatory cytokines [24].
Many targets traditionally associated with vascular
smooth muscle and ECM remodeling were not significantly
altered among these patient groups including matrix metal-
loproteinases 1, 2, 3, 7, 9 and tissue inhibitors of metallo-
proteinases 1, 2, 3 and 4. Only osteopontin, which acts as a
negative regulator of calcification in bone remodeling, was
elevated within this category with the rejoinder that OPN
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Figure 1 Significant differences in apolipoprotein A1 (APO-A1), apolioprotein B100 (APO-B100) and fibrinogen in serum from normal
and coronary artery disease (CAD) patients. Solid bars are values expressed as average plus 1 SD for APO-A1, APO-B100, and fibrinogen
obtained from patients without clinically significant coronary artery disease (normal, n = 150) based on coronary angiographic evaluation. Open
bars are results obtained from patients with CAD requiring interventional therapy (n = 209). Values are expressed in μg/ml on a logarithmic
ordinate scale and each was significantly different (*) between groups (see Table 2 for individual P values).
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Figure 2 Significant differences in vascular cell adhesion molecule, myeloperoxidase, C-reactive protein, resistin and osteopontin in
serum from normal and coronary artery disease (CAD) patients. Normal and CAD data are displayed according to Figure 1 but expressed in
ng/ml on a logarithmic ordinate scale. All comparisons represent significant statistical differences delineated in Table 2 (*) for vascular cell
adhesion molecule (VCAM-1), myeloperoxidase (MPO), C-reactive protein (CRP), resistin and osteopontin (OPN).
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also may act as a chemokine in the cell mediated type 1
immune response associated with inflammatory cell accu-
mulation rather than as a substrate for cell adhesion [25].
Thus, the proteins that demarcated our patient outcome
groups were predominantly associated with processes of
inflammation and lipid regulation rather than cellular
aggregation and ECM remodeling. However, we recognize
that the domain of proteins susceptible to interrogation in
this study was limited to analytes for which high affinity
antibody pairs precisely characterized to two different epi-
topes were available. The involvement of additional pro-
teins and pathways associated with CAD will likely be
reinforced and/or revealed as the inventory of immunoas-
says becomes more comprehensive.
Our data indicate multiplex proteomics analyses using
monoclonal antibodies provide relevant information
regarding circulating serum analyte concentrations when
assayed at a dilution that allows direct comparison to
parallel recombinant calibration standards. Advantages
include small serum volumes (< 100 μl) collected by
standard clinical protocols, rapid turnaround times
(minutes to hours), high sensitivity (pg) and a broad
dynamic range (8 logs). Disadvantages include high
assay cost, limited target availability and poor concur-
rence of concentration measurements across dilutions
and commercial platforms associated with variations in
antibodies, buffers, diluents and capture structures. In
the present study, 15 targets were tested at identical
serum dilutions using bead-based (Luminex) and planar
(Aushon) technologies in 56 identical samples, albeit
with different aliquots and in serial studies. A total of
12 assays concurred in detection of statistically signifi-
cant differences between the 2 patient outcome groups.
These results suggest that multiplex immunochemical
assays of serum may provide information of diagnostic
relevance but that protocols and reagents must be opti-
mized and standardized prior to routine clinical
application.
The results of this study were somewhat surprising both
for discovery of unique proteins as discriminants of CAD
and for the absence of statistically significant differences in
many targets with established roles in atherosclerosis. For
example, osteopontin has been only indirectly associated
with atherosclerosis yet exhibited the greatest statistical
difference between patient groups (P = 1.75 × 10-12).
Osteopontin was first identified as a sialoprotein from
mineralized bone matrix and only recently was associated
with calcification of plaques in cardiac valves and vessels
[25-27]. Similarly, resistin has been linked only indirectly
to CAD through a role in metabolic homeostasis and insu-
lin sensitivity [28]. On the other hand, multiple growth
factors (VEGF, leptin, ghrelin), lipoproteins (APO-A2, E,
serum amyloid A: SAA), cell adhesion molecules (throm-
bospondin, PECAM-1, ICAM-1, selectins E, L, P) and
MMP and TIMP targets associated with ECM remodeling
exhibited no statistically significant differences. There are
several potential explanations for the latter findings: (1) a
rigorous statistical standard was utilized to avoid multiple
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Figure 3 Significant differences in interleukin (IL)-6, IL-1b, IL-10 and N-terminal fragment pro-brain natriuretic peptide (NT-pBNP) in
serum from normal and coronary artery disease (CAD) patients. Normal and CAD data are displayed according to Figure 1 but expressed in
pg/ml on a logarithmic ordinate scale. All comparisons represent significant statistical differences (*) reported in Table 2 for IL-6, IL-1b, IL-10 and
NT-pBNP.
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testing errors and while MMP1, MMP7, ACRP-30, and
leptin were borderline for statistical significance (P =
0.015, 0.045, 0.027, 0.027 respectively) they failed to reach
the Q = 0.01 level established for significance with
adjusted P values ≤ 0.01 in this study; (2) serum may not
be an effective transducer of deleterious protein changes
participating in structural rearrangements within the cor-
onary vascular anatomy and the extracellular matrix; and
(3) the patients comprised a diverse range of coronary
obstruction and plaque vulnerability since they were
selected for symptoms upon emergent presentation
requiring diagnostic coronary angiography without the
occurrence of a clinically obvious myocardial infarct or an
‘event’. A subset of patients selected for advanced disease
might reveal additional protein changes but stray from the
intended focus of this study.
A scoring function algorithm was developed, tested and
validated for the ability to classify patients symptomatic
for heart disease consistent with the outcome of coronary
angiography studies and need for interventional therapy.
We minimized selection bias by testing a hypothesis dri-
ven biomarker panel and avoided overfitting by perform-
ing cross validation and follow-up testing utilizing
additional serum samples from the cohort. The algorithm
was designed to be ‘tuned’ to increase the sensitivity for
capture of patients who required coronary revasculariza-
tion at the expense of detecting fewer patients who did
not require coronary revascularization. All serum signa-
tures with highest classification strength from the training
trial (239 samples) included osteopontin and signatures
containing 4 or 5 proteins performed best during both
training and validation phases. The most efficacious pro-
tein signature in validation studies comprised OPN, resis-
tin, MMP7 and IFNg as a four-marker panel while the
addition of either CRP or ACRP-30 yielded comparable
results in five protein signatures.
Further validation of the diagnostic accuracy of this
approach will require extensive testing in greater numbers
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Figure 4 Receiver operating characteristics (ROC) for 2 to 5 protein panels for identification of normal patients with 95% specificity
for detection of coronary artery disease (CAD) patients. The ROC curves are derived from 4 separate panels optimized to detect 101 normal
patients (true positives in this figure) at highest specificity while maintaining a sensitivity of 95% for patients with CAD (138 samples). The ROC
curves are obtained by iteratively testing each biomarker panel for classification of a randomly excluded portion (20%) of the dataset. The areas
under the curve (AUC) were comparable as indicated in the curves for two proteins (osteopontin (OPN) and resistin: AUC = 0.839), three proteins
(OPN, resistin, apolioprotein B100 (APO-B100): AUC = 0.845), four proteins (OPN, resistin, matrix metalloproteinase 7 (MMP7) and interferon g
(IFNg): AUC = 0.839) and five proteins (OPN, resistin, MMP7, IFNg and C-reactive protein (CRP): AUC = 0.827). The predicted specificity for
detection of normal patients at 95% sensitivity for CAD patients was two proteins = 50%, three proteins = 52%, four proteins = 63% and five
proteins = 64%.
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of patients at multiple locations as well as a prognostic
cohort. It is possible that inclusion of clinical variables and
risk factors in the biomarker algorithm or using the algo-
rithm as part of a clinical scoring system will enhance both
the fidelity and the efficacy of this approach for diagnostic
purposes [29,30]. In that context, we calculated 10-year
Framingham Coronary Heart Disease (CHD) Risk Scores
for patients where all clinical variables (gender, age, total
cholesterol, HDL, systolic blood pressure, smoking and dia-
betes status, use of antihypertensive medication) were
acquired prior to coronary angiography [31]. This repre-
sented 91 patients who subsequently required therapeutic
revascularization (CAD: CHD Score = 14.9 ± 8.5) versus
63 patients who were determined to be free of significant
coronary artery disease (no CAD: CHD score = 10.2 ± 6.7).
The Framingham CHD scores were statistically different
between groups (P < 0.001, unpaired Student’s t test) but
they classified only 16% of the subjects without significant
CAD (10 of 63) at a 95% sensitivity for patients with CAD.
In contrast, our algorithm incorporating serum values for
OPN, RES, CRP, MMP7 and IFNg identified 63% of the
subjects without significant CAD (40 of 63) at 95% sensitiv-
ity for patients with CAD. Thus, our multiplex serum
protein classifier correctly identified four times as many
patients as the Framingham index. The strength of adding
clinical variables to our scoring function remains to be
determined, but the ability to exempt significant numbers
of patients with normal coronary arteries or non-significant
CAD from cardiac catheterization with a blood test repre-
sents a major economic and health benefit given the
growing epidemic of CAD in the US and abroad.
Conclusions
The results of the present study indicate that a serum,
multiplex biomarker assay may provide a clinically useful
tool in combination with other standardized clinical tests
to facilitate the decision-making process for performing
cardiac catheterization in symptomatic patients. The
development of highly sensitive monoclonal antibodies to
additional pertinent targets along with the formulation of
novel predictive algorithms will likely improve the effi-
cacy of this approach. The long-term potential benefits
include reduced patient exposure to ionizing radiation
and minimization of the rapidly escalating healthcare
costs associated with the use of invasive angiography to
rule out coronary artery disease.
Additional material
Additional file 1: Algorithm development. The analytical form of the
scoring function is provided. The testing that was performed to derive
and optimize the algorithm is described including the use of artificial
markers and cross validation testing.
Additional file 2: Predictive panel selection. The process of testing
and final derivation of the panels comprising two, three, four or five
markers that best predicted the classification outcome of the patients
based on coronary angiography is provided.
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